

OVERVIEW

- Developing novel therapeutics for infectious diseases, medical countermeasures and substance abuse
- Advancing use of Bucillamine for COVID-19 and companion long COVID diagnostic, and nerve agent exposure
- Clinical study with psilocybin for substance use disorder
- Robust patent portfolio (*16 patents and patent applications*)
- Prioritize development efforts targeting FDA regulatory incentives designations (i.e. Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease)

PRODUCT PIPELINE

Product	Indication	Stage of Development	Regulatory Status
Bucillamine <i>(Oral Tablet)</i>	Infectious Diseases COVID-19	Completed Phase 3	Determining next steps and international opps
Bucillamine <i>(Oral Tablet)</i>	Infectious Diseases Long COVID	Phase 2	IND filing for clinical study
Bucillamine	Medical Countermeasures Nerve Agent	Pre-clinical	Defence R&D Canada – Research funded by Suffield Research Centre, Canadian Department of National Defence
Oral Psilocybin <i>(Oral Capsule)</i>	Substance Use Disorder Methamphetamine	Phase 1/2	After study completion, to prepare for FDA end-of-Phase 2 meeting

STRATEGIC PARTNERS

 Bucillamine Formulation	 Bucillamine Chemical Warfare
 Psilocybin Biosynthesis	 Clinical Research Psilocybin

EXPECTED MILESTONES

- ▶ Q4-24: Results of Bucillamine for nerve agent exposure at DRDC
- ▶ Q4-24: FDA submission of Phase 2 study for Bucillamine to treat Long COVID
- ▶ Q1-25: FDA approval of Phase 2 study for Bucillamine to treat Long COVID
- ▶ Q1-25: Interim results for Phase 1/2 study for Psilocybin in Methamphetamine Disorder at University of Wisconsin
- ▶ Q1-25: Complete reformulation of Bucillamine IV for future studies in infectious diseases and rare disorders

TEAM

Management

Michael Frank, Chairman & CEO
 Carmelo Marrelli, CFO
 Derrick Welch, Advisor

Scientific and Clinical

Dr. Kelly McKee, Dr. Arshi Kizilbash, M.D., Dr. Osnesmo Mpanju, Regulatory Affairs

Directors

Michael Frank, William Jackson, Joshua Herman, Christian Scovenna and Andrew Lindzon

CONTACT INFORMATION

Revive Therapeutics Ltd.
 82 Richmond Street East
 Toronto, ON M5C 1P1

Tel: 1-888-901-0036
 E-mail: info@revivether.com
 Website: revivether.com

STOCK INFORMATION

Ticker:	CSE: RVV, OTCQB: RVVTF, FRANKFURT: 31R
Share Price:	\$0.01 <i>(Sept 19, 2024)</i>
52-week High / Low:	CAD \$0.055 / \$0.005
Shares Outstanding:	418,564,269 common shares 35,320,334 stock options 63,317,263 warrants (\$0.05 - \$0.20)
Market Cap:	CAD ~ 4,100,000